Loading, Please Wait...
EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary, will provide a corporate update at the Bank of America Merrill Lynch 2019 Healthcare Conference, being held in Las Vegas, NV, from May 14-16, 2019.
|Date:||Tuesday, May 14, 2019|
|Time:||8:00 PM Eastern Time / 5:00 PM Pacific Time|
|Location:||Las Vegas, NV - Encore Hotel|
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s MAA for its lead candidate FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency and is in development in Japan. Zogenix is preparing for a Type A meeting with the U.S. Food & Drug Administration to discuss resubmission of the company’s NDA. For more information, visit www.zogenix.com.
Senior Director, Corporate Communications
Public Relations, Syneos Health
+1 (858) 449 9575 | firstname.lastname@example.org
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com